Description
Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the comparative detection of nucleocapsid protein from SARS-CoV-2 in nasopharyngeal swab specimens.
professional use , end user only.
Please review the intended use tab for more information.
Features:
High Accuracy: nasopharyngeal swab collection with clinically proven high accuracy results
Usability: three-step, cost-effective portable testing kit
Rapid Results: Compared to standard RT-PCR tests which could take multiple days for patients to receive their results, Boson Antigen testers will show results within 15–20 minutes.
Product Information:
Quantity: 20 tests/kit
Sample type: Nasopharyngeal swab
Storage temperature: 2–30°C
Shelf life: 18 months
Test time: 15–20 minutes (do not read results after 20 minutes)
Kit Contents:
- 20 Rapid SARS-CoV-2 Antigen Test Cards (Individually packaged)
- 2 Sample Buffer
- 20 Sterilized nasopharyngeal swabs (Individually packaged)
- 20 Extraction tubes (Individually packaged)
- 1 Instruction for use
- 1 Tube rack (for 6 tubes/rack)
Intended Use
Rapid SARS-CoV-2 Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein from SARS-CoV-2 in nasal swab or nasopharyngeal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset.
Results are for the identification of SARS-CoV-2 nucleocapsid protein. Antigen is generally detectable in nasal swab or nasopharyngeal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.
The Rapid SARS-CoV-2 Antigen Test Card is intended for use by trained clinical laboratory personnel specifically instructed and trained in vitro diagnostic procedures.
professional use , end user only.
Instruction: https://www.youtube.com/watch?v=9YB2hHdJayU
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.